Becton, Dickinson and Company (NYSE: BDX) Investor Securities Class Action Lawsuit 02/27/2020

If you purchased a significant amount of shares of Becton, Dickinson and Company (NYSE: BDX) between November 5, 2019 and February 5, 2020, and / or if you purchased any NYSE: BDX shares prior to November 2019 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: April 27, 2020. NYSE: BDX investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Becton Dickinson and Company
Case Name: 
Becton Dickinson and Company Shareholder Class Action Lawsuit 02/27/2020
Case Status: 
Lawsuit Filed
Affected Securities
NYSE: BDX
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
02/27/2020
Class Period Begin: 
11/05/2019
Class Period End: 
02/05/2020
Court of Filing: 
U.S. District Court for the District of New Jersey
Deadline To File for Lead: 
04/27/2020
Summary: 

An investor in shares of Becton, Dickinson and Company (NYSE: BDX) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Becton, Dickinson and Company in connection with certain allegedly false and misleading statements made between November 5, 2019 and February 5, 2020.

Franklin Lakes, NJ based Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. Becton, Dickinson and Company reported that its Total Revenue rose from over $12.09 billion for the 12 months period that ended on September 30, 2017 to over $15.98 billion for the 12 months period that ended on September 30, 2018 and that its Net Income declined from $1.1 billion to $311 million over those respective time periods.

On February 6, 2020, Becton, Dickinson and Company lowered its fiscal 2020 guidance, expecting revenue to increase by only 1.5 to 2.5 percent, "to reflect the impact of the remediation effort and anticipated loss of sales of the Alaris infusion system." According to the Company, the software remediation plan for the Alaris system "will require additional regulatory filings," and existing customers would have "access to the Alaris System under medical necessity."

Shares of Becton, Dickinson and Company (NYSE: BDX) declined from $283.95 per share on January 29, 2020 to as low as $241.75 per share on February 6, 2020.

According to the complaint the plaintiff alleges on behalf of purchasers of Becton, Dickinson and Company (NYSE: BDX) common shares between November 5, 2019 and February 5, 2020

, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between November 5, 2019 and February 5, 2020, the defendants failed to disclose to investors that certain of Becton’s Alaris infusion pumps experienced software errors and alarm prioritization issues, that, as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to “make enhancements”, that the Company was reasonably likely to face regulatory delays in connection with the software remediation, that, as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.